Abstracts Archive - Page 2579 of 2607 - ACR Meeting Abstracts

Abstract Number: 353 • 2012 ACR/ARHP Annual Meeting
The Effect of Combination Therapy and Prednisolone On Haemostatic Markers in Rheumatoid Arthritis
Inge A.M. van den Oever¹, Danka J.F. Stuijver², Debby den Uyl³, Bregje van Zaane⁴, Marieke M. ter Wee⁵, Willem F. Lems⁵, Dirkjan van Schaardenburg¹, Joost C.M. Meijers⁴, Victor E.A. Gerdes⁴ and M. T. Nurmohamed⁶, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands, ³Rheumatology, VU University medical centre, Amsterdam, Netherlands, ⁴Internal Medicine, Slotervaart Hospital, Amsterdam, Netherlands, ⁵Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁶VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands
Background/Purpose: There is accumulating evidence that rheumatoid arthritis (RA) should be considered as prothrombotic state, explaining the increased risk of thromboembolic events. Suppressing inflammation could…
Abstract Number: 354 • 2012 ACR/ARHP Annual Meeting
Delayed Onset of Hepatitis and/or Neutropenia in Patients with Rheumatoid Arthritis Treated with Combination Therapy of Methotrexate and Leflunomide
Seung Won Choi¹, Ji Seon Oh¹, You Jae Kim², Bon San Koo², Min Wook So², Yong-Gil Kim², Chang-Keun Lee² and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: The adverse effects of combination therapy of methotrexate (MTX) and leflunomide (LEF) have been reported in many studies. Because combination of various doses of…
Abstract Number: 355 • 2012 ACR/ARHP Annual Meeting
Metaanalysis of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Transformylase (ATIC) 347C>G Polymorphism Affecting Methotrexate Efficacy and Toxicity in Rheumatoid Arthritis Patients
Fardina Malik¹ and Prabha Ranganathan², ¹Internal Medicine, Alton Memorial Hospital, Alton, IL, ²Div of Rheumatology, Washington Univ School of Med, St. Louis, MO
Background/Purpose: Methotrexate (MTX) exerts its effect in part by inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC), a key enzyme in the purine biosynthetic pathway. Published data suggests…
Abstract Number: 356 • 2012 ACR/ARHP Annual Meeting
Safety of Abatacept in Rheumatoid Arthritis with Chronic Hepatitis B VIRUS Infection
Melissa Padovan¹, Elisabetta Lanciano², Oscar Epis³, Alessandro Mathieu⁴, Giulia Erba⁵, Leopoldo Ciani⁶, Sarah Giacuzzo¹ and Marcello Govoni⁷, ¹Department if Clinical and Experimental Medicine, University of Ferrara, Section of Rheumatology, Ferrara, Italy, ²Section of Internal Medicine, Policlinico Universitario di Bari, Rheumatology Unit, Bari, Italy, ³Ospedale Niguarda Cà Granda, Rheumatology Unit, Milano, Italy, ⁴Medical Sciences, University of Cagliari, Rheumatology Unit, Cagliari, Italy, ⁵AO San Gerardo, Medical Clinics, Monza, Italy, ⁶Ospedale Civile di Legnano, Unit of Internal Medicine, Legnano, Italy, ⁷Department of Clinical and Experimental Medicine, Section of Rheumatology, Ferrara, Italy
Background/Purpose: In patients with rheumatoid arthritis (RA) concomitant hepatitis B (HBV) represents a therapeutic challenge limiting, DMARD treatment options (conventional and biologics, especially anti-TNFa and…
Abstract Number: 357 • 2012 ACR/ARHP Annual Meeting
Is the Impact of Methotrexate On Mortality in Rheumatoid Arthritis Independent of Its Effect On Disease Activity?
Dietmar MJ Krause¹, Bernadette Gabriel², Gertraud Herborn³ and Rolf Rau⁴, ¹Internistische und rheumatologische Gemeinschaftspraxis, Gladbeck, Germany, ²Private Practice, Gladbeck, Germany, ³Rheumatology, Evangelisches Fachkrankenhaus, Ratingen, Germany, ⁴Evangelisches Fachkrankenhaus, Ratingen, Germany
Background/Purpose: Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA). MTX shows effects on disease activity, radiologic progression and mortality. These…
Abstract Number: 358 • 2012 ACR/ARHP Annual Meeting
Six Months of an Attenuated Cobra Regimen (‘COBRA-light’) Is Clinically Noninferior to the Original Cobra Regimen: An Open-Label Randomized Trial in Early Rheumatoid Arthritis
Debby den Uyl¹, Marieke M. ter Wee¹, Maarten Boers², Alexandre Voskuyl³, P.J.S.M. Kerstens⁴, Mike T. Nurmohamed⁵, Hennie G. Raterman¹, Dirkjan van Schaardenburg⁵, N. van Dillen⁴, B.a.C Dijkmans¹ and W.F. Lems¹, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ³Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Reade | Jan van Breemen Research Institute, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: Early, intensive treatment of rheumatoid arthritis (RA) with combination therapy (COBRA therapy) considerably lowers disease activity and suppresses radiological progression. Although proven to be…
Abstract Number: 359 • 2012 ACR/ARHP Annual Meeting
Improved Radiological Outcome of Rheumatoid Arthritis: Early Treatment with methotrexate might be a key Prognostic Factor
Christoph Fiehn¹, Elisabeth Belke-Voss¹, Dietmar Krause², Siegfried Wassenberg³ and Rolf Rau⁴, ¹ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ²Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany, ³Rheumaklinik, Evangelisches Fachkrankenhaus Ratingen, Rheumazentrum, Ratingen, Germany, ⁴Düsseldorf, Germany
Background/Purpose: To compare the rate of radiological progression in patients with rheumatoid arthritis (RA) diagnosed in the 1980s with those of the late 1990s until…
Abstract Number: 360 • 2012 ACR/ARHP Annual Meeting
Initial Introduction of Treat-to-Target Strategy in Patients with Recent Onset Rheumatoid Arthritis Is More Effective Than Delayed Introduction of Strategy with More Clinical and Functional Remission Achieved for 2-Years: Results of the Treating to Twine Targets (T-4) Study
Yukitomo Urata¹, Yoshihide Nakamura² and Ken-ichi Furukawa³, ¹Rheumatology, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ²Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ³Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Background/Purpose: To compare the clinical, radiological and functional efficacy of initial versus delayed introduction of strategy which is treat-to-target to patients with recent onset rheumatoid…
Abstract Number: 361 • 2012 ACR/ARHP Annual Meeting
Impact of Tumour Necrosis Factor Inhibitor Treatment On Hand Bone Loss in Rheumatoid Arthritis Patients Treated in Clinical Practice. Results From the Nationwide Danish Danbio Registry
Lykke Midtbøll Ørnbjerg¹, Mikkel Østergaard², Pernille Bøyesen³, Trine David Jensen⁴, Anja Thormann², Ulrik Tarp², Wolfgang Bøhme², Ditte Dencker², Hanne M. Lindegaard⁵, Uta Engling Poulsen², Annette Hansen⁶, Vibeke Stevenius Ringsdal², Annette Schlemmer⁷, Niels Graudal², Anne Rødgaard Andersen², Jakob Espesen², Gina Kollerup², Torben Grube Christensen², Randi Pelck², Bente Glintborg², Ole Rintek Madsen², Dorte Vendelbo Jensen², Ole Majgaard² and Merete L. Hetland⁸, ¹Copenhagen Center for Arthritis Reasearch, Center for Rheumatology and Spine diseases, Glostrup Hospital, Copenhagen, Denmark, ²DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ³Rheumatology, Diakonhjemmet Hospital, Olso, Norway, ⁴Dept. of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁸Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is characterised by progressive joint destruction and periarticular bone loss. In RA patients with insufficient response to Disease-Modifying Anti-rheumatic drugs (DMARDs)…
Abstract Number: 362 • 2012 ACR/ARHP Annual Meeting
Response to Etanercept, but Not Infliximab or Adalimumab, Is Inversely Associated with Body Mass Index
James R. Maxwell¹, Darren Plant², Anne Barton², Kimme L. Hyrich³, Ann W. Morgan⁴, John Isaacs⁵ and Anthony G. Wilson⁶, ¹Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ²Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁴Section of Musculoskeletal Disease, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁵Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁶Infection and Immunity, University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Recent studies have demonstrated inverse association between BMI and radiographic severity in patients with Rheumatoid Arthritis (RA). There is also preliminary evidence that body…
Abstract Number: 363 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Radiographic Progression During TNF-Inhibitor Treatment in 932 Rheumatoid Arthritis Patients Treated in Clinical Practice: Results From the Nationwide Danish Danbio Registry
Lykke Midtbøll Ørnbjerg¹, Mikkel Østergaard¹, Pernille Bøyesen², Anja Thormann¹, Ulrik Tarp¹, Wolfgang Bøhme¹, Ditte Dencker¹, Hanne M. Lindegaard³, Uta Engling Poulsen¹, Annette Hansen⁴, Vibeke Stevenius Ringsdal¹, Annette Schlemmer⁵, Niels Graudal¹, Anne Rødgaard Andersen¹, Jakob Espesen¹, Gina Kollerup¹, Torben Grube Christensen¹, Randi Pelck¹, Bente Glintborg¹, Ole Rintek Madsen¹, Dorte Vendelbo Jensen¹, Ole Majgaard¹ and Merete L. Hetland⁶, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ²Rheumatology, Diakonhjemmet Hospital, Olso, Norway, ³Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁴Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁵Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁶Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: : Despite treatment with tumour necrosis factor inhibitors (TNFi) some rheumatoid arthritis (RA) patients progress radiographically in randomised controlled trials and observational cohorts (1).…
Abstract Number: 364 • 2012 ACR/ARHP Annual Meeting
Moderate Rheumatoid Arthritis Despite Methotrexate Treatment: Risk of Radiographic Progression
Bruno Fautrel¹, Gaia Gallo², Yves Brault³ and Henk Nab², ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²Pfizer Europe, Rome, Italy, ³Pfizer, Paris, France
Background/Purpose: Clinical remission or low disease activity are the main goals of rheumatoid arthritis (RA) treatment and European League Against Rheumatism guidelines recommend switching treatment…
Abstract Number: 365 • 2012 ACR/ARHP Annual Meeting
Improvement of Health-Related Quality of Life in RA Patients Treated with Biologics – One-Year Follow-up Data of the German Biologics Register Rabbit
Kerstin Gerhold¹, Adrian Richter², Matthias Schneider³, Hans Joachim Bergerhausen⁴, Winfried Demary⁵, Anke Liebhaber⁶, Joachim Listing⁷, Angela Zink⁸ and Anja Strangfeld⁹, ¹Programme Area of Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ⁴Klinik für Rheumatologie, Wedau Kliniken - Klinikum Duisburg, Duisburg, Germany, ⁵Private Practice, Hildesheim, Germany, ⁶Private Practice, Halle, Germany, ⁷German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ⁸Epidemiology Unit, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ⁹Programme Area Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany
Background/Purpose: Health‐related quality of life (HRQoL) has been increasingly recognized as a crucial indicator of disease burden in chronic diseases such as rheumatoid arthritis (RA).…
Abstract Number: 366 • 2012 ACR/ARHP Annual Meeting
Efficacy of Methotrexate (MTX) According to Anti-Citrullinated Protein Antibody (ACPA) Status in an Early Inflammatory Arthritis Cohort
Sarah C. Horton¹, David Pickles¹, Paul Emery¹, Maya H. Buch² and Jane E. Freeston¹, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Data suggests patients with early, ACPA negative, rheumatoid (RA) and undifferentiated arthritis (UA) are less likely to achieve remission with MTX at 4 months…
Abstract Number: 367 • 2012 ACR/ARHP Annual Meeting
Improved Fatigue-Related Quality of Life in CAPRA-2, a 12 Week Study of 5-Mg Modified (Delayed) Release Prednisone in Rheumatoid Arthritis
Rieke Alten¹, Amy Grahn², Patricia Rice³ and Frank Buttgereit⁴, ¹Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, ²Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ³Statistics, CliniRx Research, Naperville, IL, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Quality of life in rheumatoid arthritis (RA) patients can be improved by reducing the common symptom of fatigue caused by disease related factors such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].